Skip to content
Research Use OnlyThird-Party Tested in the USABatch-Verified COAsShips from the United StatesPrecision · Purity · PerformanceResearch Use OnlyThird-Party Tested in the USABatch-Verified COAsShips from the United StatesPrecision · Purity · PerformanceResearch Use OnlyThird-Party Tested in the USABatch-Verified COAsShips from the United StatesPrecision · Purity · Performance

Research use only·All materials are supplied to qualified research purchasers for in-vitro laboratory use. Not for human or veterinary use. Research Use Agreement

Analytical Testing

Retatrutide purity testing: how Pure Helix lots are analysed

Every retatrutide lot we release is tested by an independent laboratory for purity and identity, and the result is published as a lot-level certificate rather than as a marketing number.

Last scientific review
September 2026
Published by
Pure Helix

What is measured, and by which method

QuestionMethodWhat the result establishes
Is the main peak dominant?Reversed-phase HPLC, UV 214 nmArea-percent purity relative to all detected peaks
Is it the right molecule?LC-MSObserved mass matches the calculated mass for the sequence
How much is in the vial?Quantitative content assayReported peptide content in mg per vial

Purity and content are different measurements. A high area-percent purity says nothing about fill weight, and a correct fill weight says nothing about the proportion of related substances.

Published results for current retatrutide lots

Fill weightLotPurity (HPLC area %)Reported contentAssay date
10 mgPH26050199.9%11.83 mg1 June 2026
20 mgPH26050299.9%20.83 mg1 June 2026
30 mgPH26050399.9%31.03 mg31 May 2026

Each lot has its own certificate page carrying the signed source document. Reported content exceeding the nominal fill weight reflects overage in the fill, and is a measured value from the assay, not a claim about potency.

Why retatrutide is a demanding purity separation

The fatty-diacid modification makes the molecule strongly retained on C18, so a gradient tuned for unmodified peptides will compress the main peak against late-eluting related substances. The related substances that matter most for a lipidated 39-mer are deletion sequences differing by one residue, oxidation products and deamidation products — species close enough in hydrophobicity that a shallow, well-resolved gradient is required to separate them.

This is why an area-percent figure is only meaningful with its method attached, and why comparing a purity number between suppliers without the chromatographic conditions is not a comparison at all.

What these tests do not establish

  • They do not establish sterility or endotoxin status; those are separate tests that we do not claim.
  • They do not establish biological activity — potency at any receptor is a separate assay.
  • They do not establish stability over time; a certificate is a measurement on a date, and storage conditions govern what happens after it.
  • They do not make the material suitable for human or veterinary use.

Research use

Pure Helix supplies materials for laboratory research use only. Nothing on this page is medical advice, and none of the material described is for human or veterinary use.

Primary literature and standards

  1. ICH Q2(R2) — Validation of Analytical Procedures
  2. Mant CT, Hodges RS. Analysis of peptides by HPLC. Methods in Enzymology.
  3. Manning MC et al. Stability of protein pharmaceuticals: an update. Pharm Res. 2010.Degradation chemistry underlying the related substances a purity method must resolve.

Reference materials and documentation

Related reading